Brian L. Hood

Proteogenomic profiling defines progression-associated biology in high-risk endometrial cancer

Patients with high-risk endometrial carcinoma (HR-EC) experience substantial mortality despite multimodality therapy, molecular classification and contemporary care. We determined whether proteomic tumor programs capture lethal risk beyond established clinical and genomic classif...